Tuesday 30 January 2024

World-first blood test for brain cancer may increase survival rates, say experts



Inexpensive test can help diagnose even ‘inaccessible’ tumours earlier, speeding up treatment and improving outcomes





Surgeons and scientists have developed a world-first blood test for brain cancer that experts say could revolutionise diagnosis, speed up treatment and boost survival rates.

For years, brain tumours have remained notoriously difficult to diagnose. They affect hundreds of thousands of people worldwide each year, and kill more children and adults under the age of 40 in the UK than any other cancer.


Now a research team has designed a simple blood test that could help diagnose patients with even the deadliest forms of brain cancer much more quickly, potentially sparing them from invasive and high-risk surgical biopsies. The breakthrough was reported in the International Journal of Cancer.

Experts said the inexpensive liquid biopsy could also lead to earlier diagnosis, which in turn would speed up treatment and potentially increase survival rates. The test would be particularly beneficial for patients with “inaccessible” brain tumours, who could benefit from starting treatment as soon as possible, they added.

Researchers at the Brain Tumour Research Centre of Excellence, run by Imperial College London and Imperial College healthcare NHS trust, found the test could accurately diagnose a range of brain tumours, including glioblastoma (GBM), the most commonly diagnosed type of high-grade brain tumour in adults, astrocytomas and oligodendrogliomas. The test had “high analytical sensitivity, specificity and precision”, the team reported.

“This groundbreaking research could lead to earlier diagnosis and improved outcomes for brain tumour patients,” said Dan Knowles, the chief executive of the charity Brain Tumour Research.





#BrainCancer #BrainTumor #BrainCancerAwareness #FightBrainCancer #BrainCancerSupport #CureBrainCancer #GrayMatters #GoGrayInMay (May is Brain Cancer Awareness Month) #BrainTumorThursday #BrainTumorWarrior #BrainCancerJourney #BrainCancerSurvivor #BrainTumorAwarenessMonth #BTSM (Brain Tumor Social Media) #BrainTumorFighter #HopeForACure #GrayRibbon #EndBrainCancer #BrainCancerResearch #BrainTumorCommunity

Thursday 12 October 2023

Workshop to introduce functional neurosurgery







ADK Hospital has announced plans to conduct a workshop during the pre-conference of this year's Brain and Spine Conference. The workshop aims to introduce a new field of neurology in the Maldives.

The hospital said that the precursor event to the annual Brain and Spine Conference will host workshops specifically designed for doctors, nurses specializing in neurology, and other related services and affiliates.

ADK Hospital said it was targeting to introduce functional neurosurgery at this year's pre-conference workshop.

Functional neurosurgery is a specialty within neurosurgery that focuses on diseases and conditions resulting from neurochemical or electrophysiologic issues in the brain or spinal cord such as Parkinson's Disease. This specialty aims to change the chemical and electrical activity in the brain or spinal cord to improve symptoms using deep brain stimulation (DBS), responsive neurostimulation (RNS) or spinal cord stimulation.

The workshop aims to provide training and education to neurologists, neurosurgeons, radiologists, and nurses regarding brain stimulation and brain lesioning.

Training will be provided by expert doctors from Nepal, India and the United States.

Surgeons will be given practical training on how to conduct brain lesioning as well.

ADK Hospital's resident neurosurgeon Dr. Ali Niyaf said they will be conducting a new surgery on the sidelines of the Brain and Spine Conference similar to previous years.

The surgery will be a lateral lumbar interbody fusion, which involves making an incision at the side of the waist. During the procedure, the damaged disc will be removed, and the space between the bony vertebrae will be filled with a spacer bone graft.

A team of international doctors will be overseeing and instructing the surgery while prior relevant training will be provided, said Dr. Niyaf.

The surgery comes under this year's theme for the conference; "Functional neurosurgery and minimal invasive surgery".





Website: neurology.pencis.com


#Neurosurgery
#BrainSurgery
#SpineSurgery
#Neurosurgeon
#NeurologicalSurgery
#NeuroScience
#NeurologicalHealth
#NeurologicalRecovery
#NeurosurgicalTechniques
#NeuroAnatomy
#NeuroRehabilitation
#CranialSurgery
#MinimallyInvasiveSurgery
#NeurologicalCare
#BrainHealth
#SpinalHealth
#NeuroResearch
#NeurosurgicalAdvancements
#PatientCare
#BrainTumorSurgery
#SpineHealth
#NeurologicalConditions
#NeuroTech
#NeurosurgeryAwareness
#NeuroCriticalCare
#NeurologyUpdates
#NeurosurgeryTeam
#NeuroSurge





Natural methods to increase dopamine levels



Dopamine is a neurotransmitter, or chemical messenger, that forms part of the reward system the brain uses to motivate certain behaviors. It also supports motor control and executive function and helps people plan and prioritize.

When a person completes a beneficial or enjoyable behavior, neurons in the brain release dopamine. Neurons also release dopamine before an action to motivate individuals to begin.

This article discusses how to increase dopamine naturally, the signs of low dopamine levels, and when to speak with a doctor.

Eat protein

L-tyrosine, or tyrosine, is an amino acid that is a fundamental part of protein. According to a 2019 studyTrusted Source, tyrosine increases the availability of dopamine and may improve cognitive ability.

  • Dietary sources high in tyrosine include:dairy products
  • eggs
  • beans
  • whole grains
  • beef
  • lamb
  • chicken
  • fish
  • nuts

The body can also convertTrusted Source the amino acid L-phenylalanine into L-tyrosine. Phenylalanine is present inTrusted Source certain animal and cereal sources.

Reduce saturated fat intake

A 2021 review suggests diets high in saturated fat may affect dopamine release and reuptake. Long-term diets high in saturated fat may dampen dopamine signaling.

This may link to inflammation affecting dopamine neurons and lessening the effects of the neurotransmitter.

  • People can take the following steps to reduce their saturated fat intake by:eating fewer processed meat products
  • trimming excess fat from meat
  • opting for lean cuts of red meat
  • substituting meat for alternatives, such as legumes, nuts, beans, and soy products
  • choosing fish or skinless chicken
  • replacing butter, lard, or coconut oil with liquid oils, such as olive or peanut oil


#Dopamine
#DopamineRush
#Dopaminergic
#DopamineRelease
#DopaminePathways
#DopamineNeurons
#DopamineMolecule
#DopamineSystem
#DopamineFunction
#DopamineHappiness
#DopamineAndReward
#DopamineBoost
#DopamineLevels
#DopamineBalance
#DopamineRegulation
#DopamineTransporter
#DopamineReceptors
#DopamineNeurotransmitter
#DopamineDiet
#DopamineFoods
#DopamineHacks
#DopamineReleaseMechanism
#DopamineAndMotivation



Practicing this one habit daily can increase GABA level by 27% in less than one hour


Why increasing GABA level is important?





Inside the brain, there are messengers called neurotransmitters. Two important ones for anxiety are GABA and serotonin. Low levels of these chemicals can lead to anxiety, causing restlessness, insomnia and worry. Medications can help, but there's also a natural practice that increases levels by 27%

To address the same, there're medications designed to target these neurotransmitters for anxiety relief. However, there's a natural and safe practice that can increase these levels.

Research and ancient practice show that meditation can reduce anxiety and boost GABA levels. Studies, like the one from the Boston University School of Medicine, found that even less than an hour of meditation can increase GABA levels by 27%.

This simple habit can make a big difference in balancing neurotransmitters and easing anxiety.Meditation isn't just good, it's also a boost for serotonin - another important brain chemical that helps with anxiety. Studies from the University of Montreal have proven that meditation can crank up serotonin level, making us stronger against anxiety.



#GABA
#Neurotransmitter
#Anxiety
#Mood
#Relaxation
#StressRelief
#BrainHealth
#MentalHealth
#Sleep
#Calming
#GABAergic
#MoodStabilizer
#GABAReceptors
#Neuroscience
#MoodSupport
#MentalWellness
#Neurochemistry
#CalmMind
#GABABoost
#NaturalSupplements
#StressManagement

Researchers synthesize fluorescent molecularly imprinted polymeric nanoparticles to detect neurotransmitters




The animal brain consists of tens of billions of neurons or nerve cells that perform complex tasks like processing emotions, learning, and making judgments by communicating with each other via neurotransmitters. These small signaling molecules diffuse – move from high to low concentration regions – between neurons, acting as chemical messengers. Scientists believe that this diffusive motion might be at the heart of the brain's superior function. Therefore, they have aimed to understand the role of specific neurotransmitters by detecting their release in the brain using amperometric and microdialysis methods. However, these methods provide insufficient information, necessitating better sensing techniques.

To this end, scientists developed an optical imaging method wherein protein probes change their fluorescence intensity upon detecting a specific neurotransmitter. Recently, a group of researchers from Shibaura Institute of Technology in Japan led by Professor Yasuo Yoshimi has taken this idea forward. They have successfully synthesized fluorescent molecularly imprinted polymeric nanoparticles (fMIP-NPs) that serve as probes to detect specific neurotransmitters–serotonin, dopamine, and acetylcholine. Notably, developing such probes has been considered difficult so far. Their groundbreaking work, published in Volume 13, Issue 1 of the journal Nanomaterials on 3 January 2023 involves contributions from Mr. Yuto Katsumata, Mr. Naoya Osawa, Mr. Neo Ogishita, and Mr.Ryota Kadoya.

Prof. Yoshimi briefly explains the fundamentals of fMIP-NP synthesis. "It involves multiple steps. First, the target neurotransmitter to be detected is fixed on a glass beads surface. Next, monomers (building blocks of polymers) with different functions – detection, cross-linking, and fluorescence – polymerize around the beads, enveloping the neurotransmitter. The resulting polymer is then washed out to obtain a nanoparticle with the neurotransmitter structure imprinted as a cavity. It will fit only the target neurotransmitter, just like only a particular key can open a lock. Hence, fMIP-NPs can detect their corresponding neurotransmitters in the brain."

When the target neurotransmitters fit inside the cavity, the fMIP-NPs swell and get bigger. The researchers suggest that this increases the distance between the fluorescent monomers that, in turn, reduces their interactions, including self-quenching that suppresses fluorescence, with each other. As a result, the fluorescence intensity is enhanced, indicating the presence of the neurotransmitters. The researchers improved their selectivity of the detection by adjusting the neurotransmitter density on the surface of the glass beads during fMIP-NP synthesis.

Additionally, the choice of material for fixing the neurotransmitters was found to play a crucial role in the detection specificity. The researchers found that blended silane is better than pure silane for attaching the neurotransmitters, serotonin and dopamine, to the glass bead surface. The fMIP-NPs synthesized using blended silane specifically detected serotonin and dopamine. In contrast, those synthesized using pure silane resulted in non-specific fMIP-NPs that responded to non-target neurotransmitters, identifying them incorrectly as serotonin and dopamine. Likewise, poly([2-(methacryloyloxy)ethyl] trimethylammonium chloride (METMAC)-co-methacrylamide) but not METMAC homopolymer was found to be an effective dummy template of the neurotransmitter acetylcholine. While the former produced fMIP-NPs that selectively detected acetylcholine, the latter led to unresponsive nanoparticles.

These results demonstrate the feasibility of fMIP-NPs in the selective detection of neurotransmitters released in our brain. "Imaging the brain with this new technique could reveal the relationship between neurotransmitter diffusion and brain activity. This, in turn, can help us treat neurological diseases and even create advanced computers that mimics human brain functions," said Professor Yoshimi, who is enthusiastic about the innovative research.


#Neurotransmission
#Neurochemistry
#BrainChemistry
#Neuroscience
#Synapses
#Receptors
#Neurology
#Neuropharmacology
#Neuromodulation
#BrainHealth
#MoodRegulation
#NeurotransmitterImbalance
#NeurotransmitterFunction
#NeurotransmitterSystem
#NeurotransmitterResearch

What are neurotransmitters?



Neurotransmitters are often referred to as the body’s chemical messengers. They are the molecules used by the nervous system to transmit messages between neurons, or from neurons to muscles.

Communication between two neurons happens in the synaptic cleft (the small gap between the synapses of neurons). Here, electrical signals that have travelled along the axon are briefly converted into chemical ones through the release of neurotransmitters, causing a specific response in the receiving neuron.

A neurotransmitter influences a neuron in one of three ways: excitatory, inhibitory or modulatory.

An excitatory transmitter promotes the generation of an electrical signal called an action potential in the receiving neuron, while an inhibitory transmitter prevents it. Whether a neurotransmitter is excitatory or inhibitory depends on the receptor it binds to.

Neuromodulators are a bit different, as they are not restricted to the synaptic cleft between two neurons, and so can affect large numbers of neurons at once. Neuromodulators therefore regulate populations of neurons, while also operating over a slower time course than excitatory and inhibitory transmitters.

Most neurotransmitters are either small amine molecules, amino acids, or neuropeptides. There are about a dozen known small-molecule neurotransmitters and more than 100 different neuropeptides, and neuroscientists are still discovering more about these chemical messengers. These chemicals and their interactions are involved in countless functions of the nervous system as well as controlling bodily functions.

Key neurotransmitters

The first neurotransmitter to be discovered was a small molecule called acetylcholine. It plays a major role in the peripheral nervous system, where it is released by motor neurons and neurons of the autonomic nervous system. It also plays an important role in the central nervous system in maintaining cognitive function. Damage to the cholinergic neurons of the CNS is associated with Alzheimer disease.

Glutamate is the primary excitatory transmitter in the central nervous system. Conversely, a major inhibitory transmitter is its derivative γ-aminobutyric acid (GABA), while another inhibitory neurotransmitter is the amino acid called glycine, which is mainly found in the spinal cord.

Many neuromodulators, such as dopamine, are monoamines. There are several dopamine pathways in the brain, and this neurotransmitter is involved in many functions, including motor control, reward and reinforcement, and motivation.

Noradrenaline (or norepinephrine) is another monoamine, and is the primary neurotransmitter in the sympathetic nervous system where it works on the activity of various organs in the body to control blood pressure, heart rate, liver function and many other functions.

Neurons that use serotonin (another monoamine) project to various parts of the nervous system. As a result, serotonin is involved in functions such as sleep, memory, appetite, mood and others. It is also produced in the gastrointestinal tract in response to food.

Histamine, the last of the major monoamines, plays a role in metabolism, temperature control, regulating various hormones, and controlling the sleep-wake cycle, amongst other functions.




Website: neurology.pencis.com


#Dopamine
#Serotonin
#Norepinephrine
#Acetylcholine
#Glutamate
#GABA
#Endorphins
#Oxytocin
#Histamine
#Adenosine
#Epinephrine
#Anandamide
#Neurotransmission
#Neurochemistry
#BrainChemistry
#Neuroscience
#Synapses
#Receptors
#Neurology
#Neuropharmacology
#Neuromodulation






Monday 25 September 2023

Parkinson’s Onset Theory Challenged: Synaptic Dysfunction Before Neuron Death



Parkinson’s disease affects 1% to 2% of the population and is characterized by resting tremor, rigidity and bradykinesia (slowness of movement). These motor symptoms are due to the progressive loss of dopaminergic neurons in the midbrain.

The findings, which will be published Sept. 15 in Neuron, open a new avenue for therapies, the scientists said.

“We showed that dopaminergic synapses become dysfunctional before neuronal death occurs,” said lead author Dr. Dimitri Krainc, chair of neurology at Northwestern University Feinberg School of Medicine and director of the Simpson Querrey Center for Neurogenetics.

“Based on these findings, we hypothesize that targeting dysfunctional synapses before the neurons are degenerated may represent a better therapeutic strategy.”

The study investigated patient-derived midbrain neurons, which is critical because mouse and human dopamine neurons have a different physiology and findings in the mouse neurons are not translatable to humans, as highlighted in Krainc’s research recently published in Science.

Northwestern scientists found that dopaminergic synapses are not functioning correctly in various genetic forms of Parkinson’s disease. This work, together with other recent studies by Krainc’s lab, addresses one of the major gaps in the field: how different genes linked to Parkinson’s lead to degeneration of human dopaminergic neurons.

 



Neurons from PD patients with mutant parkin displayed defective recycling of synaptic vesicles, leading to accumulation of toxic oxidized dopamine that was attenuated by boosting endophilin A1 expression.

Notably, combined heterozygous parkin and homozygous PTEN-induced kinase 1 (PINK1) mutations led to earlier disease onset compared with homozygous mutant PINK1 alone, further underscoring a PINK1-independent role for parkin in contributing to disease.

Thus, this study identifies a pathway for selective activation of parkin at human dopaminergic synapses and highlights the importance of this mechanism in the pathogenesis of Parkinson’s disease.

Visit: neurology.pencis.com

#AlzheimersResearch
#BrainHealth
#CureAlzheimers
#ElderlyCare
#SeniorHealth
#MentalHealth
#AlzheimersSupport
#AlzheimersCare
#AgingPopulation
#Neurology
#MemoryCare
#WalkToEndAlz
#AlzheimersAdvocacy
#AlzheimersPrevention
#AlzheimersAwarenessMonth
#DementiaFriends
#DementiaCare
#AlzheimersWarrior

Across America, Many Who Need a Neurologist Live Too Far From Care




“Our study found a substantial travel burden exists for some people with neurologic conditions, including people living in areas with fewer neurologists and rural areas,” said study author Dr. Brian Callaghan, head of the American Academy of Neurology’s Health Services Research Subcommittee.


“We also found that people who traveled long distances were less likely to return for a follow‐up visit with a neurologist," Callaghan said in an academy news release.


Data came from more than 563,000 people on Medicare (average age: 70) who saw a neurologist at least once during the one-year study. More than 17% traveled long distances to their neurologist, averaging 81 miles one way and 90 minutes travel time.


Those who had neurologists closer to home traveled an average 13 miles to appointments. Average travel time: 22 minutes.


“Travel distance can be a serious barrier to care for people with chronic neurologic conditions,” said Dr. Carlayne Jackson, president of the American Academy of Neurology.


“The American Academy of Neurology is committed to improving access to high-quality neurologic care because consistent access to specialized care from a neurologist is essential to help people manage their symptoms and minimize risks of dangerous complications and side effects," she said in the release.


About 40% of study participants with brain and spinal cord cancers; 30% with ALS, and 23% with MS traveled long distances to appointments.


Patients in areas with the fewest neurologists -- about 10 for every 100,000 Medicare recipients -- were three times more likely to travel a long distance than people living in areas with the most neurologists, 50 per 100,000 Medicare beneficiaries.


People in rural areas were five times more likely to travel long distances than people in urban areas.


Those who traveled long distances to see their primary care physician had triple the odds of long-distance travel to see a neurologist.


Preferences also factor in.


Nearly one-third of participants bypassed the nearest neurologist by 20 miles or more, the study found. About 7% of people crossed state lines for neurologic care.


“It is possible some people bypass the nearest neurologist as a matter of preference for a particular physician or they may need to travel farther to reach neurologists with shorter wait times,” Callaghan said.



Among 165,000 participants who visited a neurologist for the first time within the study's first three months, 62,000 had at least one follow-up visit with the same neurologist. Those who traveled long distances were 26% less likely to have a follow-up visit compared to those without long-distance travel.


“Our results suggest that policymakers should investigate feasible and affordable ways to improve necessary access to neurologic care, especially in areas with low availability of neurologists and in rural communities,” said study author Chun Chieh (Anna) Lin of Ohio State University. “Interventions such as telemedicine can improve access to care. Future research should examine the differences in health outcomes between people who must travel long distances for care and those who do not.”


The study was conducted prior to the COVID-19 pandemic. Future research should look at the impact of telemedicine, the authors said.


Researchers were able to measure travel only for patients who completed neurologist visits, not those who were unable to see the doctor. The results may not be the same for people not covered by Medicare.




Visit: neurology.pencis.com




#Neurology
#Neurologist
#NeuroScience
#BrainHealth
#NeuroResearch
#NeurologicalDisorders
#NeurologicalCare
#NeurologyNews
#NeurologyConference
#NeurologyClinic
#NeurologicalTreatment
#NeurologyUpdate
#NeurologyEducation
#NeurologyAwareness
#NeurologicalAdvancements
#NeurologyCommunity
#NeurologyCases
#BrainDiseases
#NeurologicalSymptoms

Neuro News Roundup: World Alzheimer Day

 



Alzheimer Agent Blarcamesine Shows Significant Reduction of Amyloid-ß Biomarkers in Phase 2b/3 Trial

Newly announced findings from a follow-up analysis to the phase 2b/3 study (NCT03790709) assessing blarcamesine (Anavex Life Sciences), an investigational therapy, demonstrated a significant reduction in pathological amyloid-ß levels in plasma, as well as a significant slowing in the rate of pathological brain atrophy on MRI scans in treated patients with early AD.1

In the study, blarcamesine-treated patients showed significant increases in validated biomarkers of amyloid-ß pathology, plasma Aβ42/40 ratio (P = .048), further demonstrating the agent’s strong antiamyloid effect. Additionally, MRI findings showed significant reduction in brain volume loss, including whole brain (P = .0005), when blarcamesine was comparedwith placebo.

The trial was a multicenter, randomized, double-blind, placebo-controlled, phase 2b/3 study that enrolled 508 participants with early symptomatic AD. The participants, recruited from 52 medical research centers and hospitals in 5 countries, were randomized to receive blarcamesine (n = 338) or placebo (n = 170) oral capsules once daily for 48 weeks. The Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) subscales were used as primary end points to assess the cognitive and functional efficacy of blarcamesine. Using a mixed model for repeated measures, all prespecified clinical end points were analyzed.


Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis

Alzheon, the drug makers of ALZ-801, announced positive topline data from its phase 2 biomarker study (NCT04693520), with findings that showed significant reductions in plasma phosphorylated tau (p-tau) levels and improved cognitive scores after 2 years of treatment with the agent. Patients on ALZ-801 also demonstrated a statistically significant reduction in measures of hippocampal volume in comparison with an external control arm of matched ADNI patients, which were consistent with previously reported 12-month data.2

The open-label, single-arm phase 2 trial included 84 patients with early-stage AD who carried either 1 or 2 copies of the ε4 allele of apolipoprotein E gene (APOE3/4 heterozygotes and APOE4/4 homozygotes, respectively) and were treated over a 104-week period. Treatment with the agent resulted in a statistically significant 43% reduction in plasma p-tau181 (P <.009) after 52 weeks and a 31% reduction at week 104 (P <.045). Plasma amyloid-ß42 levels decreased throughout the treatment period, reaching a statistically significant 4% reduction from baseline (P <.042) at week 104, while the reduction in plasma Aß40 levels stabilized at 52 weeks at a new homeostatic level.

After 104 weeks of treatment, patients showed a statistically significant 28% reduction in hippocampal volume (P <.015) in comparison with external controls from the Alzheimer Disease Neuroimaging Initiative (ADNI). Controls from the ADNI which were matched based on APOE4 genotype, age, gender, and disease stage following FDA guidance from August 2023 on the use of real-world data and real-world evidence to support regulatory decision-making for drugs and biological products.


Visit: neurology.pencis.com

#Alzheimers
#EndAlz
#AlzheimersAwareness
#Dementia
#ForgetMeNot
#MemoryLoss
#Caregiver
#AlzheimersResearch
#BrainHealth
#CureAlzheimers
#ElderlyCare
#SeniorHealth
#MentalHealth
#AlzheimersSupport
#AlzheimersCare
#AgingPopulation
#Neurology
#MemoryCare
#WalkToEndAlz
#AlzheimersAdvocacy

Brain Activity Decoder Can Reveal Stories in People’s Minds








Beginning with an earlier version of the paper that appeared as a preprint online, the researchers addressed questions about potential misuse of the technology. The paper describes how decoding worked only with cooperative participants who had participated willingly in training the decoder. Results for individuals on whom the decoder had not been trained were unintelligible, and if participants on whom the decoder had been trained later put up resistance — for example, by thinking other thoughts — results were similarly unusable.

“We take very seriously the concerns that it could be used for bad purposes and have worked to avoid that,” Tang said. “We want to make sure people only use these types of technologies when they want to and that it helps them.”

In addition to having participants listen or think about stories, the researchers asked subjects to watch four short, silent videos while in the scanner. The semantic decoder was able to use their brain activity to accurately describe certain events from the videos.

The system currently is not practical for use outside of the laboratory because of its reliance on the time need on an fMRI machine. But the researchers think this work could transfer to other, more portable brain-imaging systems, such as functional near-infrared spectroscopy (fNIRS).

“fNIRS measures where there’s more or less blood flow in the brain at different points in time, which, it turns out, is exactly the same kind of signal that fMRI is measuring,” Huth said. “So, our exact kind of approach should translate to fNIRS,” although, he noted, the resolution with fNIRS would be lower.






This work was supported by the Whitehall Foundation, the Alfred P. Sloan Foundation and the Burroughs Wellcome Fund.

The study’s other co-authors are Amanda LeBel, a former research assistant in the Huth lab, and Shailee Jain, a computer science graduate student at UT Austin.

Alexander Huth and Jerry Tang have filed a PCT patent application related to this work.




Visit: neurology.pencis.com



#Neuroscience
#BrainResearch
#NeuroTech
#BrainActivity
#BrainDecoder
#NeuroImaging
#CognitiveScience
#BrainMapping
#NeuroData
#BrainWave
#NeuralNetworks
#BrainScience
#Neuroinformatics
#EEG (Electroencephalography)
#fMRI (Functional Magnetic Resonance Imaging)
#Neurology
#Neurotechnology
#BrainSignals
#MindMapping
#NeuralResearch

Tuesday 19 September 2023

5 best mattresses for back pain relief and better sleep


How can a mattress help back pain?

A mattress plays a crucial role in back pain management. A good mattress provides adequate support to the spine and reduces pressure on sensitive areas, allowing muscles to relax and heal during sleep. Proper spinal alignment and support ensure a restorative sleep, minimising discomfort.

Which type of mattress is best for back pain management?

According to market leaders, memory foam and orthopedic mattresses are the best choices for back pain management. While memory foam conforms to your body’s shape, reducing pressure points, orthopedic mattresses offer specialised support for the spine and lower back. If you are still confused about how to choose the best mattress for back pain, make the choice as per your sleep preferences while prioritising support and comfort.

Best mattress for back pain relief

We have curated a list of the best mattresses for back pain relief in India. By choosing one of these mattresses, you can take a significant step towards improving your sleep and managing back pain effectively.

1. The Sleep Company SmartGRID Ortho 5 Inch Mattress Single Size

The Sleep Company SmartGRID Ortho mattress is a technology-backed solution for back pain relief. It is powered by the SmartGRID technology, a grid-like structure that dynamically adapts to the contours of your body. This ensures that your spine stays aligned throughout the night, reducing pressure on your lower back and shoulders. The 2000+ air channels allow cooling comfort.

A firm orthopedic mattress, it comes with a removable and washable cover that adds a layer of protection against dust and spillage. This no-sagging product comes with a 10-year warranty against manufacturing defects.


2. Doctor Dreams by Nilkamal Plus Memory Foam 6 Inch Orthopaedic Mattress

The Doctor Dreams by Nilkamal Orthopaedic Mattress combines memory foam and high-density foam layers to deliver optimal comfort and support. This medium firm mattress is supported by ergonomically designed PU foam, comforting memory foam and knitted fabric for a relaxed and refreshing sleep.

Its high-density foam base provides durability and long-lasting support, making it a worthwhile investment for your overall well-being.


3. Livpure Smart Ortho CurvX Memory Foam Mattress

The Livpure Smart Ortho CurvX Mattress is designed with 5D Sleeptech technology that is focused on body and spine support. From head and neck tp lower legs and ankles, your entire body will get the comfort of the unique features of this mattress for back relief. It comes embedded with 16 biohealing crystals and made in breathable fabric for a cooling effect.

The memory foam conforms to your body’s curves, aligning your spine and reducing discomfort.

48% OFF

4. Springfit Club Class Platinum Orthopedic Back Pain Relief Dual Comfort Medium Soft & Hard Bed Mattress 6 Inch

A reversible mattress with high relisience foam, the Springfit Club Class Platinum Orthopedic Mattress offers a unique dual-comfort feature with medium-soft and hard sides. This flexibility allows you to choose the level of support that suits your back pain needs.

While the medium-soft side provides a plush feel, while the hard side offers robust support to your lumbar region. It’s a versatile choice for couples with different comfort preferences.

11% OFF

5. Wakefit Mattress Orthopedic Mattress

Wakefit’s Orthopedic Mattress features next gen memory foam and high-density foam that adapt to the shape and weight of your body. It is hypoallergenic, and keeps you protected by being resistant to bed bugs. Its breathable fabric cover, ensuring a comfortable and pain-free night’s sleep. This mattress is backed by a 10-year warranty, reflecting its durability and long-term benefits. The breathable fabric cover promotes airflow and temperature regulation, ensuring comfortable sleep.

 

Test Your Knowledge: How Does Universal Screening for Dyslexia in Schools Work?

 


How many students are estimated to have dyslexia or other language-based disorders? How does universal screening for dyslexia in schools work? Test your knowledge by taking our quiz.

Once you complete the quiz, you can see how your score compares to your peers, get detailed explanations of the correct answers, and find additional reading and resources on the topic.

Follow our Special Education tag to explore more Education Week coverage on special education. 

 

How Much Do You Know About Universal Dyslexia Screening? Test Your Knowledge

An estimated ________ students have dyslexia or some other language-based disorder.  

1.

An estimated ________ students have dyslexia or some other language-based disorder.  

1 in 30
1 in 20
1 in 10
1 in 5

As of October of 2022, ___ states had enacted dyslexia-related legislation. 

2.

As of October of 2022, ___ states had enacted dyslexia-related legislation. 

12
25
31
46

True/False: Dyslexia screening that takes place within a school setting is intended to diagnose dyslexia.

3.

True/False: Dyslexia screening that takes place within a school setting is intended to diagnose dyslexia.

True
False

Among public schools that aren’t using evidence-based reading instruction, dyslexia screenings are likely to find risk indicators of dyslexia in about __________ of students.

4.

Among public schools that aren’t using evidence-based reading instruction, dyslexia screenings are likely to find risk indicators of dyslexia in about __________ of students.

11 percent
34 percent
50 percent
62 percent

Formal evaluators of dyslexia must be able to:

5.

Formal evaluators of dyslexia must be able to:

Administer assessments
Interpret evaluation data
Provide input on appropriate reading interventions
All of the above

True/False: Once a student has been diagnosed with dyslexia and qualifies for special education services, a school team will create an individualized education program (IEP) for the student.

6.

True/False: Once a student has been diagnosed with dyslexia and qualifies for special education services, a school team will create an individualized education program (IEP) for the student.

True
False

 

Thursday 14 September 2023

A boy saw 17 doctors over 3 years for chronic pain.

 


The beginning of the end of the journey came earlier this year, when Courtney finally got some answers from an unlikely source, ChatGPT. The frustrated mom made an account and shared with the artificial intelligence platform everything she knew about her son's symptoms and all the information she could gather from his MRIs.

“We saw so many doctors. We ended up in the ER at one point. I kept pushing,” she says. “I really spent the night on the (computer) … going through all these things."

So, when ChatGPT suggested a diagnosis of tethered cord syndrome, "it made a lot of sense," she recalls.

 

Pain, grinding teeth, dragging leg

When Alex began chewing on things, his parents wondered if his molars were coming in and causing pain. As it continued, they thought he had a cavity.

“Our sweet personality — for the most part — (child) is dissolving into this tantrum-ing crazy person that didn’t exist the rest of the time,” Courtney recalls.

The dentist “ruled everything out” but thought maybe Alex was grinding his teeth and believed an orthodontist specializing in airway obstruction could help. Airway obstructions impact a child’s sleep and could explain why he seemed so exhausted and moody, the dentist thought. The orthodontist found that Alex’s palate was too small for his mouth and teeth, which made it tougher for him to breathe at night. She placed an expander in Alex’s palate, and it seemed like things were improving.

“Everything was better for a little bit,” Courtney says. “We thought we were in the home stretch.”

But then she noticed Alex had stopped growing taller, so they visited the pediatrician, who thought the pandemic was negatively affecting his development. Courtney didn’t agree, but she still brought her son back in early 2021 for a checkup.

"He'd grown a little bit," she says.

The pediatrician then referred Alex to physical therapy because he seemed to have some imbalances between his left and right sides.

“He would lead with his right foot and just bring his left foot along for the ride,” Courtney says.

But before starting physical therapy, Alex had already been experiencing severe headaches that were only getting worse. He visited a neurologist, who said Alex had migraines. The boy also struggled with exhaustion, so he was taken to an ear, nose and throat doctor to see if he was having sleep problems due to his sinus cavities or airway.

No matter how many doctors the family saw, the specialists would only address their individual areas of expertise, Courtney says.

“Nobody’s willing to solve for the greater problem,” she adds. “Nobody will even give you a clue about what the diagnosis could be.”

Next, a physical therapist thought that Alex could have something called Chiari malformation, a congenital condition that causes abnormalities in the brain where the skull meets the spine, according to the American Association of Neurological Surgeons. Courtney began researching it, and they visited more doctors — a new pediatrician, a pediatric internist, an adult internist and a musculoskeletal doctor — but again reached a dead end.

In total, they visited 17 different doctors over three years. But Alex still had no diagnosis that explained all his symptoms. An exhausted and frustrated Courtney signed up for ChatGPT and began entering his medical information, hoping to find a diagnosis.

“I went line by line of everything that was in his (MRI notes) and plugged it into ChatGPT,” she says. “I put the note in there about ... how he wouldn’t sit crisscross applesauce. To me, that was a huge trigger (that) a structural thing could be wrong.”

She eventually found tethered cord syndrome and joined a Facebook group for families of children with it. Their stories sounded like Alex's. She scheduled an appointment with a new neurosurgeon and told her she suspected Alex had tethered cord syndrome. The doctor looked at his MRI images and knew exactly what was wrong with Alex.

“She said point blank, ‘Here’s occulta spina bifida, and here’s where the spine is tethered,” Courtney says.

Tethered cord syndrome occurs when the tissue in the spinal cord forms attachments that limit movement of the spinal cord, causing it to stretch abnormally, according to the American Association of Neurological Surgeons. The condition is closely associated with spina bifida, a birth defect where part of the spinal cord doesn’t develop fully and some of the spinal cord and nerves are exposed.

With tethered cord syndrome, “the spinal cord is stuck to something. It could be a tumor in the spinal canal. It could be a bump on a spike of bones. It could just be too much fat at the end of the spinal cord,” Dr. Holly Gilmer, a pediatric neurosurgeon at the Michigan Head & Spine Institute, who treated Alex, tells TODAY.com. "The abnormality can’t elongate ... and it pulls.” 

In many children with spina bifida, there’s a visible opening in the child’s back. But the type Alex had is closed and considered “hidden,” also known as spina bifida occulta, according to the U.S. Centers for Disease Control and Prevention.

 

Website: neurology.pencis.com 

 

 #ChronicPain #PainManagement #ChronicIllness #InvisibleIllness #ChronicPainWarrior #PainRelief #ChronicPainLife #PainAwareness #LivingWithPain #ChronicPainSupport #ChronicPainAwareness #PainSucks #PainWarrior #ChronicPainJourney #PainFree #PainCommunity #PainCoping